Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 11:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 1,933 matching trials from the live ClinicalTrials.gov search.
Conditions
Alzheimer Disease
Interventions
rosiglitazone
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
55 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Seattle, Washington
Conditions
TTR-mediated Amyloidosis
Interventions
Revusiran (ALN-TTRSC)
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Cleveland, Ohio
Conditions
Alzheimer Disease
Interventions
ACC-001+ QS21 (3mcg), ACC-001 (10 mcg) + QS-21, ACC-001+QS-21 (30mcg)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
28
States / cities
Phoenix, Arizona • Sun City, Arizona • San Francisco, California + 10 more
Conditions
Alzheimer Disease
Interventions
300 mg [C14] CT1812
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Conditions
Alzheimer's Disease
Interventions
Individualized management of AD including caregiver training, Memantine
Behavioral · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Completed Phase 1Phase 2 Interventional Results available

Effect of CT1812 Treatment on Brain Synaptic Density

NCT03493282
Conditions
Alzheimer Disease
Interventions
Active Treatment- CT1812 100 mg, Active Treatment- CT1812 300 mg, Placebo
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
50 Years to 85 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Recruiting Not applicable Interventional Accepts healthy volunteers

Gamma-Music Based Intervention for Mild Alzheimer's Disease

NCT05984524
Conditions
Alzheimer Disease
Interventions
Gamma-Music Based Intervention
Behavioral
Lead sponsor
Northeastern University
Other
Eligibility
50 Years to 95 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
AL Amyloidosis
Interventions
NEOD001, Placebo
Drug
Lead sponsor
Prothena Biosciences Ltd.
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
19
States / cities
Duarte, California • Stanford, California • Denver, Colorado + 15 more
Conditions
Alzheimer's Disease
Interventions
BMS-241027, Placebo matching BMS-241027
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
50 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
15
States / cities
Anaheim, California • Long Beach, California • San Francisco, California + 11 more
Conditions
Alzheimer's Disease
Interventions
saracatinib, Placebo
Drug
Lead sponsor
Stephen M. Strittmatter
Other
Eligibility
50 Years to 90 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Not applicable Interventional Accepts healthy volunteers

A Scalable Nutrition Adherence Intervention

NCT06121986
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Adherence
Interventions
Improving Cognitive Aging through Nutrition (ICAN) Adherence Program, Improving Cognitive Aging through Nutrition, Mediterranean diet
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
55 Years to 85 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Tallahassee, Florida
Completed Early Phase 1 Interventional Accepts healthy volunteers

Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein

NCT03071224
Conditions
Alzheimer Disease, Healthy Volunteers
Interventions
[18F] MNI-946, [18F]Florbetapir
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Not listed Not applicable Interventional

Couples Coping With Alzheimer's Disease

NCT00438724
Conditions
Aging, Alzheimer Disease, Dementia
Interventions
Information, counseling and support
Behavioral
Lead sponsor
Alzheimer's Association
Other
Eligibility
21 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
New York, New York
Conditions
Alzheimer's Disease
Interventions
Home based occupational therapy, Best practices primary care
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
45 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Alzheimer's Disease
Interventions
Avagacestat, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
45 Years to 90 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
50
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 39 more
Conditions
Alzheimer Disease
Interventions
[11C] Pittsburgh Compound-B (PIB)
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Completed No phase listed Observational

Lactate for Energy and Neurocognition

NCT05207397
Conditions
Healthy Aging, Alzheimer Disease
Interventions
Lactate infusion
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
60 Years to 95 Years
Enrollment
24 participants
Timeline
2023 – 2024
U.S. locations
1
States / cities
Kansas City, Kansas
Completed Not applicable Interventional Results available

Socially Isolated Older Adults Living With Dementia

NCT03666624
Conditions
Alzheimer Disease, Dementia
Interventions
Personalized care network
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Dementia Alzheimer's Type
Interventions
Sargramostim GZ402664, Placebo, Florbetapir F18
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Houston, Texas
Conditions
Alzheimer Disease
Interventions
bapineuzumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 89 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
16
States / cities
Phoenix, Arizona • Encino, California • Delray Beach, Florida + 11 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

REVEAL III: Risk Evaluation and Education for Alzheimer's Disease

NCT00462917
Conditions
Alzheimer Disease
Interventions
Pleiotropic info, in-person disclosure, AD-only info, in-person disclosure, Pleiotropic info, phone disclosure, AD-only info, phone disclosure
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
290 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Ann Arbor, Michigan + 1 more
Conditions
Memory Loss (Excluding Dementia), Lifestyle (Sedentary Behavior and Physical Activity), Lifestyle Risk Reduction, Healthy Lifestyle Behaviors, Dementia Prevention
Interventions
My Healthy Brain
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Boston, Massachusetts
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

R21 Roche: 3-Way Tau Tracers in AD

NCT05464368
Conditions
Alzheimer Disease
Interventions
[18F]RO-948, 18F-MK6240, 18F-GTP1
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years to 100 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Completed No phase listed Observational Accepts healthy volunteers

Genetic Studies in Familial Dementia

NCT04680013
Conditions
Dementia of Alzheimer Type, Alzheimer Disease, Late Onset, Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Dementia
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
4,884 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2024
U.S. locations
1
States / cities
Miami, Florida